# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Processa Pharma (NASDAQ:PCSA) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.0...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Processa Pharma (NASDAQ:PCSA) with a Buy and maintains $6 pric...
Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde®Studies support potential benefit as an impro...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharma (NASDAQ:PCSA) with a Buy and lowers the price t...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Processa Pharma (NASDAQ:PCSA) with a Buy and maintains $8 pric...